18 . 06 .2025
Press release
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
06 . 06 .2025
Press release
RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years
23 . 04 .2025
Press release
Galderma shareholders approve all Annual General Meeting proposals
17 . 04 .2025
Press release
Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®
15 . 04 .2025
Press release
Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets
20 . 03 .2025
Press release
AMWC 2025: Galderma pushes the innovation frontier with updates from its unparalleled portfolio designed to meet the needs of the aesthetic community
14 . 03 .2025
Press release
Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds
03 . 03 .2025
Press release
AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum
18 . 02 .2025
Press release
Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis
31 . 01 .2025
Press release
IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™)